The best indicator for CVS Health (CVS)
We backtested 20 indicators across daily, weekly and hourly charts on real CVS Health (CVS) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
SMA 50/200 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for CVS Health (CVS) over ~53.3 years — trailing buy-and-hold by 1.6% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | SMA 50/200 Cross ✓ | Daily | 8.4% | 0.47 | -52.5% | 38.2% | 34 | -1.6% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 8.2% | 0.47 | -49.4% | 52.4% | 21 | -1.6% |
| 3 | Rate of Change ✓ | Weekly | 7.9% | 0.47 | -47.1% | 52.1% | 169 | -2.0% |
| 4 | EMA 50/200 Cross ✓ | Daily | 7.9% | 0.45 | -57.2% | 45.5% | 33 | -2.1% |
| 5 | EMA 20/50 Cross ✓ | Daily | 6.7% | 0.42 | -58.0% | 44.1% | 118 | -3.3% |
| 6 | Holy Grail Confluence ✓ | Daily | 6.3% | 0.42 | -62.0% | 76.3% | 93 | -3.6% |
| 7 | Donchian Midline ✓ | Weekly | 6.3% | 0.4 | -65.6% | 44.5% | 146 | -3.6% |
| 8 | Bollinger Mean-Reversion ✓ | Daily | 5.4% | 0.39 | -63.6% | 66.8% | 226 | -4.6% |
| 9 | ADX / DMI ✓ | Weekly | 5.4% | 0.39 | -54.7% | 48.6% | 74 | -4.4% |
| 10 | Holy Grail Confluence ✓ | Weekly | 5.4% | 0.39 | -66.7% | 88.9% | 18 | -4.4% |
| 11 | RSI Trend (>50) ✓ | Weekly | 5.6% | 0.36 | -67.8% | 44.2% | 147 | -4.3% |
| 12 | Donchian Breakout ✓ | Weekly | 4.9% | 0.35 | -43.1% | 48.9% | 45 | -5.0% |
| 13 | WaveTrend (8/6/4) ✓ | Daily | 4.4% | 0.31 | -63.9% | 70.9% | 196 | -5.5% |
| 14 | Bollinger Breakout ✓ | Weekly | 3.5% | 0.3 | -44.0% | 46.4% | 56 | -6.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For CVS Health (CVS), SMA 50/200 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.